Cite this article as: O'Hara MH, Messersmith W, Kindler H, Zhang W, Pitou C, Szpurka AM, Wang D, Peng S-B, Vangerow B, Khan AA, Koneru M, Wang-Gillam A (2020) Safety and pharmacokinetics of CXCR4 peptide antagonist, LY2510924, in combination with durvalumab in advanced refractory solid tumors, Journal of Pancreatic Cancer 6:1, 21–31, DOI: 10.1089/pancan.2019.0018. This evidence concerns the gene CXCR4 and familial pancreatic carcinoma.